Huifang (Linda) Lu, MD, PhD
Department of General Internal Medicine, Division of Internal Medicine
Present Title & Affiliation
Primary Appointment
Professor, Department of GIM, Section of Rheumatology and Clinical Immunology, The University of Texas MD Anderson Cancer Center, Houston, TX
Dual/Joint/Adjunct Appointment
Professor, Department of GIM, Section of Rheumatology and Clinical Immunology, The University of Texas MD Anderson Cancer Center, Houston, TX
Education & Training
Degree-Granting Education
| 1995 | Baylor College of Medicine, Houston, Texas, US, Immunology and Microbiology, Ph.D |
| 1988 | Beijing Medical University, Beijing, CN, MD |
Postgraduate Training
| 2002-2005 | Clinical Fellowship, Immunology, Allergy and Rheumatology, Baylor College of Medicine, Houston, Texas |
| 1999-2002 | Clinical Residency, Internal Medicine Internship and Residency, Austin Medical Educational Programs, Austin, Texas |
| 1996-1999 | Research Fellowship, Department of Human and Molecular Genetics, Baylor College of Medicine, Houston, Texas |
| 1995-1996 | Research Fellowship, Leukocyte Biology, Department of Pediatrics, Baylor College of Medicine, Houston, Texas |
Licenses & Certifications
| 2006 | American Board of Allergy and Immunology |
| 2005 | American Board of Rheumatology |
| 2005 | Texas Medical License |
| 2002 | American Board of Internal Medicine |
| null | Georgia Composite Medical Board |
| null | Mississippi State Board of Medical Licensure |
| null | Alabama Board of Medical Examiners |
| null | Oklahoma State Board of Medical Licensure |
| null | Tennessee Board of Medical Examiners |
| null | Louisiana State Board of Medical Examiners |
| null | Arizona Board of Medical Examiners |
| null | Florida Board of Medicine |
Experience & Service
Faculty Academic Appointments
Associate Professor, Department of GIM, Section of Rheumatology and Clinical Immunology, The University of Texas MD Anderson Cancer Center, Houston, TX, 2012 - 2018
Assistant Professor, Department of GIM, Section of Rheumatology and Clinical Immunology, The University of Texas MD Anderson Cancer Center, Houston, TX, 2005 - 2012
Administrative Appointments/Responsibilities
Secretary, Basic Clinical Immunology Interest Section, American Academy of Allergy Asthma and Immunology, 2025 - Present
Site Director, Resident Rheumatology Rotation, Baylor/MDA Internal Medicine Residency Program, University of Texas MD Anderson Cancer Center, 2016 - Present
Member, Program Evaluation Committee, Baylor/MDA Rheumatology Joint Fellowship, University of Texas MD Anderson Cancer Center, 2015 - Present
Chair, Institutional Chemotherapy Hypersensitivity Reaction Algorithm Task Force, University of Texas MD Anderson Cancer Center, 2014 - Present
Course Chair, Rheumatology Difficult Case and Treatment Planning Conference, University of Texas MD Anderson Cancer Center, 2010 - Present
Coordinator, Fellow Education, Joint Baylor / MD Anderson Rheumatology Fellowship, University of Texas MD Anderson Cancer Center, 2010 - Present
Course Chair, Joint Baylor College of Medicine / MD Anderson Rheumatology Fellowship, Multidisciplinary "Radiology/Rheumatology" 2-year curriculum, University of Texas MD Anderson Cancer Center, 2010 - Present
Co-Chair, Multidisciplinary Bone Health Center Steering Committee, University of Texas MD Anderson Cancer Center, 2009 - Present
Other Professional Positions
Data Safety Monitoring Board consultant, Cellenkos, InC, Houston, TX, 2019 - 2022
Co-Director, Multidisciplinary Bone Health Program Clinic, University of Texas MD Anderson Cancer Center, TX, 2013 - Present
Extramural Institutional Committee Activities
Member, Survivorship Research Advisory Workgroup, The University of Texas MD Anderson Cancer Center, 2022 - Present
Member, Data Safety Monitoring Board (Clinical Research), The University of Texas MD Anderson Cancer Center, 2022 - Present
Member, Professional Education Committee, The University of Texas MD Anderson Cancer Center, 2021 - Present
Elected Member, PRS Faculty Compensation & Benefit Advisory Committee, The University of Texas MD Anderson Cancer Center, 2021 - 2023
Elected Member, Faculty Senate, The University of Texas MD Anderson Cancer Center, 2020 - Present
Member, Scientific Review Committee, The University of Texas MD Anderson Cancer Center, 2020 - 2021
Member, Cancer Survivorship Research Advisory Committee, The University of Texas MD Anderson Cancer Center, 2016 - 2020
Member, CME Advisory Committee, The University of Texas MD Anderson Cancer Center, 2015 - 2020
Member, Division of Internal Medicine Grand Rounds Planning Committee, The University of Texas MD Anderson Cancer Center, 2014 - Present
Member, Institutional Chemotherapy/Biotherapy Policy Task Force, The University of Texas MD Anderson Cancer Center, 2011 - 2020
Member, Pharmacy & Therapeutic Committee, The University of Texas MD Anderson Cancer Center, 2010 - 2022
Elected Member, Credentials Committee of the Medical Staff, The University of Texas MD Anderson Cancer Center, 2010 - 2013
Member at Large, Medical Records Committee, The University of Texas MD Anderson Cancer Center, 2006 - 2010
Honors & Awards
| 2025 - Present | Certificate of Clinical Educator Excellence |
| 2022 | Excellence in Education Award, The University of Texas MD Anderson Cancer Center |
| 2022 | Rheumatology Research Foundation Mentored Nurse Practitioner/Physician Assistant Award, American College of Rheumatology |
| 2021 | Mentor for the "Mentoring Up" Program, The University of Texas MD Anderson Cancer Center |
| 2018 | The 14th Annual Chamberlain Mentor Award, The University of Texas MD Anderson Cancer Center |
| 2016 | Fellow, American Academy of Allergy, Asthma & Immunology |
| 2014 - 2016 | Rolanette and Berdon Lawrence Bone Disease Research Award, Texas Bone Program |
| 2014 - 2016 | Cancer Survivorship Research Seed Award, The University of Texas MD Anderson Cancer Center |
| 2014 | Conquer Cancer Foundation merit award for outstanding abstract, American Society of Clinical Oncology |
| 2014 | Webster Jee Young Investigator Award for Clinical Research, 7th International Conference on Osteoporosis and Bone Research |
| 2012 | James S. and Suzanne Cyrus Scholar Award for Clinical Research, The University of Texas MD Anderson Cancer Center |
| 2011 | Best Poster Presentation, Second Place, Rolanette and Berdon Lawrence Bone Disease Program Annual Scientific Retreat |
| 2007 | Silver Award of Best Abstract, The 5th International Conference on Bone & Mineral Research and The 7th International Osteoporosis Symposium |
| 2005 | NIH Institutional National Research Service Award NIAID, T32 A1 053831 "Physician-Scientist Training Grant", 2004 - 2005, National Institute of Health |
| 2005 | Research Fellowship Award ($40,000 one of four awarded nationally), GlaxoSmithKline |
| 2004 | Travel award to the State-of-the-Art Annual Symposium, American College of Rheumatology |
| 2002 - 2004 | Clinical Fellowship of the Future Care Award ($100,000 one of two per year nationally), American Academy of Allergy Asthma and Immunology Pfizer/UCB Pharma |
| 1996 - 1999 | National Individual Service Award - F32-HL009657-01, National Institute of Heart Lung and Blood |
Professional Memberships
Selected Presentations & Talks
Local Presentations
- 2014. Assessment of Fracture Following Hematopoietic Stem Cell Transplantation. Conference. Rolantte and Berdon Lawrence Bone Disease Program Annual Scientific Retreat. Houston, TX, US.
National Presentations
- 2025. Effector CD8+ T cells and PD-1hi CXCL13hi CD4+ T Cells Contribute to Recurrent Immune Checkpoint Inhibitor Mediated Inflammatory Arthritis. Poster. ACR Convergence. Chicago, Illinois, US.
- 2024. Immune Related Adverse Reactions Due to Checkpoint Inhibitors. Invited, US.
- 2023. Baseline screening bone mineral density at the time of initiating aromatase inhibitor therapy in women with breast cancer is associated with decreased fracture risk. Invited. 12th Edition of Webinar on Breast Cancer, US.
- 2022. Learning Needs Assessment for Patients with Cancer and a Pre-Existing Autoimmune Disease Who Are Candidates to Receive Immune Checkpoint Inhibitors. Conference. American College of Rheumatology Annual Meeting, PA, US.
- 2022. Bone Health in Bone Marrow Transplant Survivors. Invited. BMT InfoNet Survivorship Symposium. Zoom, US.
- 2022. Aromatase Inhibitor-Induced Inflammatory Myopathies: A Case Series. Invited. 10th Edition Webinar on Breast Cancer, US.
- 2017. Women with Breast Cancer Initiating Therapy with Aromatase Inhibitors Reduces Subsequent Fracture Risk. Poster Tour Presentation. Invited. European League Against Rheumatism (EULAR) 2017 Annual Meeting. Madrid, Spain, US.
- 2016. Bone Health in Cancer Survivors. Invited. Onco-Internal Medicine Symposium. Houston, TX, US.
- 2014. High Incidence of Osteoporotic Fractures Following Hematopoietic Stem Cell Transplantation. Invited. Plenary Session.
International Presentations
- 2019. Drug Allergy in Cancer and Cancer Treatment. Invited. Hangzhou International Symposium of Oncology 2019, CN.
- 2018. Drug Allergies. Invited. International Oncology Summit. Kumming, CN.
- 2017. Osteoporotic fracture risk assessment using FRAX following hematopoietic stem cell transplantation. Invited. European League Against Rheumatism (EULAR) Annual Meeting. Madrid, ES.
- 2014. Fracture Risk Assessment Following Hematopoietic Stem Cell Transplantation. Invited. The 7th International Conference on Osteoporosis and Bone research. Xiamen, CN.
- 2013. Current Issues in Osteoporosis Treatment. Invited. The 11th Intl Conference on Bone and Mineral Research & The 13th Intl Osteoporosis Symposium. Guangzhou, CN.
- 2007. Chemotherapy Is Associated with Increased Risk of Osteoporosis and Fracture in Elderly Patients. Invited. The 5th Intl Conference on Bone and Mineral Research & The 7th Intl Osteoporosis Symposium. Urumqi-Xinjiang, CN.
- 1999. LFA-1 is Sufficient in Mediating Neutrophil Emigration in Mac-1 Deficient Mice. Invited. Plenary Session. Berlin, DE.
Formal Peers
- 2017. Primary Immune Deficiency. Invited. Houston, TX, US.
- 2017. Vitamin D Updates. Invited. Houston, TX, US.
- 2013. Cancer and Osteoporosis. Invited. Houston, TX, US.
- 2012. Survivorship: Rheumatology Related Issues. Invited, TX, US.
- 2011. Bone and Rheumatology Related Issues. Invited. Victoria, TX, US.
- 2008. Rheumatologic Paraneoplastic Syndromes. Invited. Houston, TX, US.
Grant & Contract Support
| Date: | 2024 - Present |
| Title: | A Phase 1/2, Open-Label Study to Evaluate the Safety and Efficacy of Autologous CD19-specific Chimeric Antigen Receptor T cells in Subjects with Active Idiopathic Inflammatory Myopathy |
| Funding Source: | Cabaletta Bio |
| Role: | Site-Principal Investigator |
| Date: | 2024 - Present |
| Title: | Immunogenicity and clinical efficacy of 20-valent pneumococcal conjugate vaccine in lymphoma survivors after treatment with anti-CD20 therapy |
| Funding Source: | Cancer Survivorship Research Seed Grant |
| Role: | Co-PI |
| Date: | 2024 - Present |
| Title: | A Phase 1/2, Open-Label Study of NK Cell Therapy for Autoimmune Disorders: Systemic Sclerosis, Systemic Lupus Erythematosus, and Lupus Nephritis |
| Funding Source: | Institute for Cell Therapy Discovery & Innovation Fund |
| Role: | Co-PI |
| ID: | 2024-0208 |
| Date: | 2023 - Present |
| Title: | Cab-201-001/Reset-SLE: A phase 1/2, open label study to evaluate the safety and efficacy of autologous CD19-specific chimeric antigen receptor T cells in subjects with active systemic lupus erythematosus |
| Funding Source: | Cabaletta Bio |
| Role: | Site-Principal Investigator |
| ID: | Caba |
| Date: | 2014 - 2016 |
| Title: | Fracture assessment following hematopoietic stem cell transplantation for hematologic malignancies |
| Funding Source: | Rolanette and Berdon Lawrence Bone Disease Clinical Research Award |
| Role: | PI |
| Date: | 2014 - 2016 |
| Title: | Cancer Survivorship Research Seed Award: Evaluation of the WHO Fracture Risk Assessment Tool in predicting fractures following hematopoietic stem cell transplantation in patients with underlying hematologic malignancy |
| Funding Source: | UT MD Anderson Cancer Center |
| Role: | PI |
| Date: | 2012 - 2014 |
| Title: | Cyrus Clinical Research Award: Osteoporosis and fractures in patients who received stem cell transplant |
| Funding Source: | UT MD Anderson Cancer Center |
| Role: | PI |
| Date: | 2008 - 2016 |
| Title: | A randomized, controlled study of lbandronate for the prevention of bone loss in patients received allogeneic bone marrow transplantation for hematological disorder and malignancies |
| Funding Source: | Roche Laboratories |
| Role: | PI |
| ID: | 2006-0960 |
| Date: | 2008 - 2011 |
| Title: | Long term assessment of arthralgias in breast cancer patients using Aromatase Inhibitors |
| Funding Source: | Astrazeneca |
| Role: | Co-Chair |
| ID: | 2006-1038 |
| Date: | 1996 - 1999 |
| Title: | ICAM-1 and Beta 2 Integrins in Antigen Induced Asthma |
| Funding Source: | National Institute of Heart Lung and Blood |
| Role: | PI |
| ID: | F32-HL009657-01 |
Selected Publications
Peer-Reviewed Articles
- Lopez-Olivo MA, Duan Z, Lu H, Volk RJ, Ostrin EJ, Xu Y, Giordano S, Zhao H. Lung cancer screening uptake in patients with rheumatoid arthritis in community settings. Cancer Prev Res (Phila), 2026. e-Pub 2026. PMID: 42627193.
- Keam S, Li YJ, Chu Y, Tayar JH, Lu H, Wu M, Agarwal SK, Jain N, Msaouel P, Diab A, Wang L, Haymaker C, Nurieva R, Kim ST. Immune hallmarks of recurrent immune checkpoint inhibitor-mediated inflammatory arthritis. Cancer Immunol Res, 2026. e-Pub 2026. PMID: 42536056.
- Mildred Kwan MD, Blanka M Kaplan MD, Krista Shaw MD, Veronica Alix MD, Vishaka R Hatcher MD, Isma Shah MD, Donald S Levy MD, Allison E Norton MD, Aarti Pandya MD, Pope PhD SM, Howard M Rosenblatt MD, Sara Anvari MD, Jolan Walter MD, Maya Jerath MD, Huifang Linda Lu MD. Vaccination for Patients With Immunosuppression and Altered Immunity: A Workgroup Report from the AAAAI Adverse Reactions to Drugs, Biologics, and Vaccines Committee and the Autoimmunity and Altered Immune Response Committee. The Journal of Allergy and Clinical Immunology: In Practice, 2026.
- Trager S, Chemaly RF, Ahmed S, Lu H, Nze C, Heredia EA, Khawaja F. Humoral responses to two versus one dose of pneumococcal conjugate vaccine 20 (PCV20) in lymphoma survivors at 3 months follow up, 2026. e-Pub 2026.
- Gan, Q, Ding, Y, Wu, Y, Zhang, Y, Meng, QH, Ding, Q, Lu, H, Shelburne, S, Ehlers II, RA, Han, XY. Infections Due to Corynebacterium kroppenstedtii With Focus on Granulomatous Lobular Mastitis for Tissue Specificity, Pathogenesis, Bacteriologic Workup, and Treatment. Archives of pathology & laboratory medicine 149(9):812-821, 2025. e-Pub 2025. PMID: 39800878.
- Lopez-Olivo, MA, Matusevich, AR, Tayar, JH, Lu, H. Managing Rheumatoid Arthritis in Older Adults with Cancer. Drugs and Aging 42(7):599-614, 2025. e-Pub 2025. PMID: 40382733.
- Christopher Boldt, Lu H. More Than Medicine: The Hope, Hurdles, and Hidden Costs of IgG Therapy. Journal of Immunotherapy and Precision Oncology, 2025. e-Pub 2025.
- Lopez-Olivo MA, Karpes Matusevich AR, Tayar JH, Lu H. Managing Rheumatoid Arthritis in Older Adults with Cancer. Drugs Aging, 2025. e-Pub 2025.
- Boldt C, Prasad P, Lu H. Drug-Induced Liver Injury After Zoledronic Acid Infusion and Literature Review. The Journal of Clinical Endocrinology & Metabolism, 2025. e-Pub 2025.
- Gan Q, Ding X, Wu Y, Ding QQ, Zhang Y, Meng QH, Lu H, Shelburne SA, Richard A Ehlers II, Han XY. Infections Due to Corynebacterium Kroppenstedtii with Focus on Granulomatous Lobular Mastitis for Tissue Specificity, Pathogenesis, Bacteriologic Workup and Treatment. Archives of Pathology & Laboratory Medicine 2025, 2025. e-Pub 2025.
- Lopez-Olivo MA, Suarez-Almazor ME, Duhon GF, Cherry M, Lu H, Calabrese C, Altan M, Tawbi H, Meara A, Bingham CO, Diab A, Leal VB, Volk RJ. Development of an Educational Website for Patients With Cancer and Preexisting Autoimmune Diseases Considering Immune Checkpoint Blockers: Usability and Acceptability Study. JMIR Cancer 10:e53443, 2024. e-Pub 2024. PMID: 39454185.
- Hanif IH, Abdelrahim S, Al Shaarani M, Lu H, Ahmad R, Goswami S, Abudayyeh A. Immune Checkpoint Therapy-Induced Lupus Nephritis. Kidney Int Rep 9(5):1534-1537, 2024. e-Pub 2024. PMID: 38707799.
- Lopez-Olivo, MA, Suarez-Almazor, M, Duhon, GF, Cherry, M, Lu, H, Calabrese, C, Altan, M, Tawbi, H, Meara, A, Bingham, CO, Diab, A, Leal, VB, Volk, R. Development of an Educational Website for Patients With Cancer and Preexisting Autoimmune Diseases Considering Immune Checkpoint Blockers. JMIR Cancer 10, 2024. e-Pub 2024.
- Bowman S, Barcenas CH, Lu H. Aromatase Inhibitors and their Connection to Autoimmunity. J Cancer Immunol 6(1):40-43, 2024. e-Pub 2024.
- Lopez-Olivo MA, Kachira JJ, Buni M, Kim ST, Lu H, Tayar JH, Duhon GF, Ruiz JI, Bingham CO, Calabrese C, Volk RJ, Suarez-Almazor ME. Learning Needs of Patients with Cancer and a Pre-Existing Autoimmune Disease Who Are Candidates to Receive Immune Checkpoint Inhibitors. Cancers (Basel) 15(15), 2023. e-Pub 2023. PMID: 37568819.
- Fa'ak F, Buni M, Falohun A, Lu H, Song J, Johnson DH, Zobniw CM, Trinh VA, Awiwi MO, Tahon NH, Elsayes KM, Ludford K, Montazari EJ, Chernis J, Dimitrova M, Sandigursky S, Sparks JA, Abu-Shawer O, Rahma O, Thanarajasingam U, Zeman AM, Talukder R, Singh N, Chung SH, Grivas P, Daher M, Abudayyeh A, Osman I, Weber J, Tayar JH, Suarez-Almazor ME, Abdel-Wahab N, Diab A. Selective immune suppression using interleukin-6 receptor inhibitors for management of immune-related adverse events. J Immunother Cancer 11(6), 2023. e-Pub 2023. PMID: 37328287.
- Wilson NR, Jain P, Gomez JA, Lu H, Pemmaraju N. Concurrent myelodysplasia and monoclonal B lymphocytosis in VEXAS syndrome. Leuk Res 2022 Sep;120:106909 doi: 10.1016/j.leukres.2022.106909, 2022. e-Pub 2022.
- Otani IM, Lehman HK, Jongco AM, Tsao LR, Azar AE, Tarrant TK, Engel E, Walter JE, Truong TQ, Khan DA, Ballow M, Cunningham-Rundles C, Lu H, Kwan M, Barmettler S. Practical guidance for the diagnosis and management of secondary hypogammaglobulinemia: A Work Group Report of the AAAAI Primary Immunodeficiency and Altered Immune Response Committees. J Allergy Clin Immunol 149(5):1525-1560, 2022. e-Pub 2022. PMID: 35176351.
- Kim ST, Chu Y, Misoi M, Suarez-Almazor ME, Tayar JH, Lu H, Buni M, Kramer J, Rodriguez E, Hussain Z, Neelapu SS, Wang J, Shah AY, Tannir NM, Campbell MT, Gibbons DL, Cascone T, Lu C, Blumenschein GR, Altan M, Lim B, Valero V, Loghin ME, Tu J, Westin SN, Naing A, Garcia-Manero G, Abdel-Wahab N, Tawbi HA, Hwu P, Oliva ICG, Davies MA, Patel SP, Zou J, Futreal A, Diab A, Wang L, Nurieva R. Distinct molecular and immune hallmarks of inflammatory arthritis induced by immune checkpoint inhibitors for cancer therapy. Nature Communications 13(1):1970, 2022. e-Pub 2022. PMID: 35413951.
- Bowman S, Lu H. Aromatase Inhibitor-Induced Inflammatory Myopathies: A Case Series. Joint Bone Spine 89(2):105308, 2022. e-Pub 2021. PMID: 34774793.
- Lu H, Pundole X, Lee HC. The role of bone modifying agents in myeloma bone disease. JBMR Plus https://doi.org/10.1002/jbm4.10518(8):e10518, 2021. e-Pub 2021. PMID: 34368608.
- Lu H, Lei X, Zhao H, Elting L, Siricilla M, Ursani MA, Giordano SH, Suarez-Almazor M. Bone Mineral Density at the Time of Initiating Aromatase Inhibitor Therapy is Associated with Decreased Fractures in Women with Breast Cancer. J Bone Miner Res 36(5):861-871, 2021. e-Pub 2021. PMID: 33484602.
- Messer A, Drozd B, Glitza IC, Lu H, Patel AB. Dermatomyositis associated with nivolumab therapy for melanoma: a case report and review of the literature. Dermatol Online J 26(8), 2020. e-Pub 2020. PMID: 32941716.
- Figgins B, Primeaux B, Shank BR, Chen SE, Weber DM, Lu H. Cyclophosphamide desensitization in patients with severe hypersensitivity reactions to bendamustine. J Oncol Pharm Pract 26(4):1078155219867127, 2020. e-Pub 2020. PMID: 31433727.
- Mamlouk O, Selamet U, Machado S, Abdelrahim M, Glass WF, Tchakarov A, Gaber L, Lahoti A, Workeneh B, Chen S, Lin J, Abdel-Wahab N, Tayar J, Lu H, Suarez-Almazor M, Tannir N, Yee C, Diab A, Abudayyeh A. Nephrotoxicity of immune checkpoint inhibitors beyond tubulointerstitial nephritis: single-center experience. J Immunother Cancer(2019 Jan 6;7(1):2. doi: 10.1186/s40425-018-0478-8):2, 2019. e-Pub 2019. PMID: 30612580.
- Lu H, Lok AS, Warneke CL, Ahmed S, Torres HA, Martinez F, Suarez-Almazor ME, Foreman JT, Ferrajoli A, Hwang JP. Passive transfer of anti-HBc after intravenous immunoglobulin administration in patients with cancer: a retrospective chart review. Lancet Haematol 5(10):e474-e478, 2018. e-Pub 2018. PMID: 30290904.
- Pundole X, Lopez-Olivo, M, Lu H. Calcium and vit D supplements and fracture in community-dwelling adults. JAMA 319(19):2041-2042, 2018. e-Pub 2018.
- Pundole X, Murphy WA, Ebede CC, Karim E, Manocha S, Don-Pedro D, Rondon G, Leung CH, Liu S, Du XL, Champlin RE, Lu H. Fracture risk prediction using FRAX in patients following hematopoietic stem cell transplantation. Arch Osteoporos 13(1):38, 2018. e-Pub 2018. PMID: 29619576.
- Wilmas K, Aria A, Torres-Cabala C, Lu H, Duvic M. Schnitzler’s syndrome in a patient with a family history of monoclonal gammopathy. Dermatology Online Journal 24(1):5, 2018. e-Pub 2018.
- des Bordes JKA, Suarez-Almazor ME, Volk RJ, Lu H, Edwards B, Lopez-Olivo MA. Online Educational Tool to Promote Bone Health in Cancer Survivors. J Health Commun 22(10):808-817, 2017. e-Pub 2017. PMID: 28922062.
- Pundole X, Cheema HI, Petitto GS, Lopez-Olivo MA, Suarez-Almazor ME, Lu H. Prevention and treatment of bone loss and fractures in patients undergoing a hematopoietic stem cell transplant: A systematic review and meta-analysis. Bone Marrow Transplant 52(5):663-670, 2017. e-Pub 2017. PMID: 28112742.
- Pundole X, Lopez-Olivo MA, Suarez-Almazor ME, Lu H. Anti-sclerostin antibodies for the treatment of osteoporosis (Protocol). Cochran Database of Systematic Reviews 2017(4 Article Number: CD012640. DOI: 10.1002/14651858. CD012640), 2017. e-Pub 2017.
- Edwards BJ, Sun M, West DP, Guindani M, Lin YH, Lu H, Hu M, Barcenas C, Bird J, Feng C, Saraykar S, Tripathy D, Hortobagyi GN, Gagel R, Murphy WA. Incidence of atypical femur fractures in cancer patients: The MD Anderson Cancer Center Experience. J Bone Miner Res 31(8):1569-76, 2016. e-Pub 2016. PMID: 26896384.
- Sasaki K, Popat U, Jain P, Kadia T, Patel K, Patel K, Jain N, Takahashi K, Young K, Miranda RN, Oo TH, Lu H, Pemmaraju N. Successful treatment of aplastic anemia-paroxysmal nocturnal hemoglobinuria associated with eosinophilic fasciitis with matched unrelated donor allogeneic peripheral blood stem cell transplantation. Clin Case Rep 4(8):765-7, 2016. e-Pub 2016. PMID: 27525080.
- Lu H, Champlin RE, Popat U, Pundole X, Escalante CP, Wang X, Qiao W, Murphy WA, Gagel RF. Ibandronate for the prevention of bone loss after allogeneic stem cell transplantation for hematologic malignancies: A randomized controlled trial. Bonekey Rep 5:843, 2016. e-Pub 2016. PMID: 28018583.
- Pundole X, Barbo A, Lin H, Champlin RE, Lu H. Increased incidence of fractures in recipients of hematopoietic stem-cell transplantation. J Clin Oncol 33(12):1364-1370, 2015. e-Pub 2015. PMID: 25779562.
- Lopez-Olivo MA, Lu H, Tayar JH. Review of tofacitinib in rheumatoid arthritis. Clin Invest (Lond.) 5(1):23-38, 2015. e-Pub 2015.
- Pundole X, Konoplev S, Hlaing Oo T, Lu H. Autoimmune myelofibrosis and systemic lupus erythematosus in a middle-aged male presenting only with severe anemia: A case report. Medicine (Baltimore) 94:1-4, 2015. e-Pub 2015. PMID: 25984660.
- Pundole XN, Partow K, Lu H. Denosumab increases bone mineral density in a young osteoporotic woman on dialysis after allogeneic stem cell transplantation for hematologic malignancy. BoneKey 58(5), 2014. e-Pub 2014.
- Shi Q, Giordano SH, Lu H, Saleeba AK, Malveaux D, Cleeland CS. Anastrozole-associated joint pain and other symptoms in patients with breast cancer. J Pain 14(3):290-6, 2013. e-Pub 2013.
- Pundole XN, Lu H. A case of mediastinal epithelioid hemangioendothelioma associated with hypertrophic osteoarthropathy and literature review. Thoracic Cancer(4):457–460, 2013. e-Pub 2013.
- Lu, H, Pundole XN, Vu K. Baseline Characteristics Predictive of Malignancy among Patients Presenting with Lymphadenopathy: A Cancer Center Experience. Clin Cancer Investig J(2):325-9, 2013. e-Pub 2013.
- Lu, H, Marengo MF, Suarez-Almazor ME. Rare case of septic arthritis caused by Candida Krusei: a case report and review of the literature. J Rheumatol 39(6):1308-9, 2012. e-Pub 2012.
- Yang T, Mendoza-Londono R, Lu H, Tao J, Li K, Keller B, Jiang MM, Shah R, Chen Y, Bertin TK, Engin F, Dabovic B, Rifkin DB, Hicks J, Jamrich M, Beaudet AL, Lee B. E-selectin lignad-1 regulates growth plate homeostasis in mice by inhibiting the intracellular processing and secretion of mature TGF-beta. J Clin Invest 7(120):2474-85, 2010. e-Pub 2010.
- Lu H, Hu MI, Gagel RF. Cancer therapies and bone health. Curr Rheumatology Rep 12(3):177-85, 2010. e-Pub 2010.
- Santos FP, Konoplev SN, Lu H, Vertovsek S. Primary autoimmune myelofibrosis in a 36-year-old patient presenting with isolated extreme anemia. Leuk Res 1(34), 2010. e-Pub 2010.
- Cabanillas M, Lu H, Fang S, Du XL. Elderly patients with non-Hodgkin lymphoma who receive chemotherapy are at higher risk for osteoporosis and fractures. Leuk Lymphoma 48(8):1514-21, 2007. e-Pub 2007.
- Berrios-Rivera JP, Lu H, Fang S, Cabanillas ME, Cabanillas F, Hu H, Du XL. Variations in chemotherapy and radiation therapy in a large nationwide and community-based cohort of elderly patients with non-Hodgkin's lymphoma. Am J Clin Oncol 30(2):163-71, 2007. e-Pub 2007.
- Yang Y, Xiong Z, Zhang S, Yan Y, Nguyen J, Ng B, Lu, H, Yang X. Bcl-nl inhibits T-cell apoptosis induced by expression of SARS coronavirus E protein in the absence of growth factors, 2005. e-Pub 2005.
- S-H L, Prince JE, Rais M, Kheradmand F, Shardonofsky F, Lu H, Smith W, Soong L. Differential requirements for CD18 in T helper effector homing. Nat Med 9(10):1281-1286, 2003. e-Pub 2003.
- Lu H, Huston DP. Clinical Trial Reports on Immunodeficiency. Current Allergy Asthma Reports 3(5):375-377, 2003. e-Pub 2003.
- Forlow SB, White EJ, Barlow SC, Feldman SH, Lu H, Bagby GJ, Beaudet AL. Severe inflammatory defect and reduced viability in CD18 and E-selectin double mutant mice. J Clin Invest 106(12):1457-1466, 2000. e-Pub 2000.
- Lu H, Ballantyne C, Smith CW. LFA-1 (CD11/CD18) triggers hydrogen peroxide production by canine neutrophils. J Leuk Biol 68:73-80, 2000. e-Pub 2000.
- Lu H, Youker K, Entman ML, Ballantyne C, Smith CW. Hydrogen peroxide induces LFA-1-dependent neutrophil adhesion to cardiac myocytes. Am J Physiology 278(3):H835-42, 2000. e-Pub 2000.
- Ding ZM, Babensee JE, Simon SI, Lu H, Perrard JL, Bullard DC, Dai XY, Bromley SK, Dustin ML, Entman ML, Smith CW, Ballantyne CM. Relative contribution of LFA-1 and Mac-1 to neutrophil adhesion and migration. J Immunol 163(9):5029-38, 1999. e-Pub 1999.
- Scharffeter K, Lu H, Norman K, van Nood N, Munoz F, Grabbe S, McArthur M, Kaplan S, Ley K, Smith CW, Montgomery CA, Rich S, Beaudet AL. Spontaneous skin ulceration and defective T cell function in CD18 null mice. J Exp Med 188:119-131, 1998. e-Pub 1998.
- Lu H, Smith CW, Perrard JL, Bullard D, Tan L, Shappell SB, Entman ML, Beaudet AL, Ballantyne CM. LFA-1 is sufficient in mediating neutrophil emigration in Mac-1 deficient mice. J Clin Invest 99:1340-1350, 1997. e-Pub 1997.
- Gopalan PK, Smith CW, Lu H, Berg EL, McIntire LB, Simon SI. Neutrophil CD18-dependent arrest on intercellular adhesion molecule 1 (ICAM-1) in shear flow can be activated through L-selectin. J Immunol 158:367-375, 1997. e-Pub 1997.
- Manning AM, Lu H, Kukielka GL, Oliver MG, Toman CA, Krater S, Drong RF, Slightom JL, Ballantyne CM, Entman ML, Smith CW, Anderson DC. Molecular cloning and comparative sequence analysis of canine ICAM-1. Gene 24:102-120, 1996. e-Pub 1996.
- Burns AR, Simon SI, Kukielka GL, Rowen JL, Lu H, Mendoza LH, Brown ES, Entman ML, Smith CW. Chemotactic factors stimulate CD18-dependent canine neutrophil adherence and motility on lung fibroblasts. J Immunol 156:3389-3401, 1996. e-Pub 1996.
- Stevens AM, Y-y W, Sieger KA, Lu H, L-y Y. Biphasic transcriptional regulation of the interferon regulatory factor-1 gene by prolactin: involvement of gamma-interferon-activated sequence and Stat-related proteins. Mol. Endocrinol 9:513-525, 1995. e-Pub 1995.
Invited Articles
- Lu H, Pundole XN. How Cancer Affects Your Bones. Coping Magazine 9(20), 2013. e-Pub 2013.
Review Articles
- Lu H. Glucocorticoid-induced Osteoporosis. Newsletter, Department of Endocrine Neoplasia and Hormone Disorders. 3rd ed. United States of America, 2009. e-Pub 2009.
Professional Educational Materials
- Lu H. Teaching Manual: How to Order Laboratory Tests for Autoimmune Disease, UT MD Anderson Cancer Center, 2011.
- Lu H. Teaching Manual: Bone Health Evaluation and Treatment Algorithm, UT MD Anderson Cancer Center, 2011.
- Lu H, Hu M, Gagel RF. Bone Health Video and Brochure, 2010. Awarded with Silver Medal by the National Health Information Awards, 2010.
- Lu H, et al. Patient education handouts on Osteoporosis, Bone Health, Calcium Supplementation, Reclast, and Prolia, 2010.
- Lu H. Rheumatology Consult at MD Anderson - Orientation: A How To Manuel, 2007.
Other Articles
- Boldt, C, Lu, H More Than Medicine. Journal of Immunotherapy and Precision Oncology 8(3):191-193, 2025. PMID: 40927307.
- Kim, ST, Chu, Y, Misoi, MW, Suarez-Almazor, M, Tayar, JH, Lu, H, Buni, M, Kramer, J, Rodriguez, E, Hussain, Z, Neelapu, SS, Wang, RJ, Shah, AY, Tannir, NM, Campbell, M, Gibbons, DL, Cascone, T, Lu, C, Blumenschein, GR, Altan, M, Lim, B, Valero, V, Loghin, ME, Tu, J, Westin, SN, Naing, A, Garcia-Manero, G, Hassan, NA, Tawbi, H, Hwu, P, Oliva, IC, Davies, MA, Patel, SP, Zou, J, Futreal, A, Diab, A, Wang, L, Nurieva, R Author Correction. Nature communications 15(1), 2024. PMID: 38965214.
Abstracts
- Li J, Buni M, Lu H, Tayar J, Assassi S. Raynaud’s phenomenon in the setting of immune checkpoint inhibitors: a case series and possible implications. World Scleroderma Congress 11(1):194, 2026. e-Pub 2026.
- Lopez-Olivo,Angeles, Duan,Zhigang, Lu H, Ostrin,Edwin Justin, Volk,Robert, Xu,Ying, Giordano,Sharon Hermes, Zhao,Hui, Hubbard,Desarae. Lung Cancer Screening with Rheumatoid Arthritis: A Retrospective Claims Analysis. ACR 2025, 2025. e-Pub 2025.
- Gan Q, Ding X, Wu Y, Ding QQ, Zhang Y, Meng QH, Lu H, Shelburne SA, Richard A Ehlers II, Han XY. Granulomatous Lobular Mastitis due to Corynebacterium Kroppenstedtii: Tissue Specificity, Pathogenesis, Microbiologic Workup and Treatment. United States & Canadian Academy of Pathology’s 114th Annual Meeting. e-Pub 2025.
- Gajagowni S, Rawther-Karedath A, Varughese S, Ren W, Alhalabi O, Campbell MT, Gubbiotti M, Lawson BC, Lu H, Aaroe A, Ahattacharjee M, Sheth RA, Subudhi SK, Siddiqui BA. Core Needle Biopsy for Diagnosis of Immune-Medicated Myocarditis. Society for Immunotherapy of Cancer, 2024. e-Pub 2024.
- Thimmapuram R, Buni M, Lu H, Tayar J, Li J, Suarez-Almazor M, Rico R, Turner N, Nurieva R. Identification of Biomarkers Predicting Steroid Resistance in Immune Checkpoint Inhibitor-Induced Arthritis. American College of Rheumatology, 2023. e-Pub 2023.
- Siddiqui BA, Palaskas N, Sheth R, Basu S, Tummala S, Lu HL, Hosing C, Rawther-Karedath A, Yadav SS, Sharma P, Subudhi SK. Identifying molecular targets for rational immunosuppressive strategies in severe immune checkpoint therapy-induced myocarditis, myositis, and myasthenia gravis. International Cancer Immunotherapy Conference, 2022. e-Pub 2022.
- Fa'ak F, Zobniw C, Buni M, Lu H, Falohun A, Trinh A, Awiwi MO, Elsayes KM, Ludford K, Dimitrova M, Sandigursky S, Cunningham-Bussel A, Sparks JA, Abu-Shawer O, Thanarajasingam U, Zeman AM, Talukder R, Singh N, Chung SH, Grivas P, Daher M, Abudayyeh A, Johnson D, Suarez-Almazor M, Rahma OE, Weber JS, Tayar JH, Diab A, Abdel-Wahab N. Selective immune suppression using interleukin-6 blockade in immune related adverse events. Journal for ImmunoTherapy of Cancer 9(Suppl 3):A853-A853. DOI:10.1136/jitc-2021-SITC2021.816, 2021. e-Pub 2021.
- Saberian C, Fa'ak F, Tayar JH, Buni M, Kim S, Lu H, Suarez-Almazor M, Gruschkus S, Daher M, Kaysia Ludford K, Johnson D, Abdel-Wahab N, Diab A. Interleukin-6 receptor blockade for management of immune checkpoint inhibitor related adverse events in patients with melanoma. Journal for ImmunoTherapy of Cancer 8(Suppl 3):A694-A694. DOI:10.1136/jitc-2020-SITC2020.0657, 2020. e-Pub 2020.
- Kim ST, Tayar J, HL L, Suarez-Almazor M, Rodriguez E, Manero SS, Tawbi HA, Hwu P, Diab A, Nurieva R. Expansion of IL-17 Producing CD4+ T Cells in Synovial Fluid From Patients With Arthritis Resulting From Combination Therapy of PD-1 and CTLA-4 Inhibitors. Keystone Symposia Conference(Breckenridge, CO), 2019. e-Pub 2019.
- Kim ST, Tayar J, HL L, Suarez-Almazor M, Y-Z Z, Rodriguez E, Neelapu S, Wang J, Shah AY, Tannir N, Gibbons DL, Manero SS, Tawbi HA, Hwu P, Futreal A, Diab A, Nurieva R, Zhongshan L. Enrichment of IL-17 Producing CD4+ T Cells in Synovial Fluid from Patients with Arthritis after Anti-CTLA-4 and anti-PD-1 Combination Therapy. Arthritis Rheumatol, 2019. e-Pub 2019.
- Kim S, Tayar J, Lu H, Wang J, Gibbons D, Garcia-Manero G, Hwu P, Diab A, Nurieva R. Characterization of Lymphoid Cells in Synovial Fluid from Cancer Patients with ImmunotherapyInduced. 2018 ACR/ARHP Annual Meeting, in Chicago, IL, 2018. e-Pub 2018.
- Kim ST, Nurieva R, Tayar JH, Huifang HL, Wang J, Dibbons D, Garcia-Manero GG, Suarez Almazor M, Hwu P, Diab A. Characterizatization of Lymphoid Cells in Synovial Fluid from Cancer Patients with Immunotherapy-Associated Arthritis. J Immunother Cancer(Suppl), 2018. e-Pub 2018.
- Abdel-Wahab N, Tayar JH, Diab A, Kim ST, Lu H, Suarez-Almazor ME. The Outcome of Checkpoint Inhibitor Therapy in Patients with Cancer and Solid Organ Transplant: A Systematic Review of the Literature 36(Suppl 5S), 2018. e-Pub 2018.
- Abdel-Wahab N, Tayar JH, Diab A, Kim ST, Lu H, Suarez-Almazor ME. Inflammatory Arthritis Induced by the use of Checkpoint Inhibitors for Immunotherapy of Cancer. Journal for ImmunoTherapy of Cancer(Suppl 5), 2017. e-Pub 2017.
- Lu H, Murphy WA, Edebe CC, Karim E, Rondon G, Leung CH, Liu S, Champlin RE, Pundole X. Assessing intervention thresholds for osteoporotic fracture using FRAX in patients following a hematopoietic stem cell transplantation. ASBMR Annual Meeting 2017, 2017. e-Pub 2017.
- Lu H, Murphy WA, Karim E, Manocha S Don-Pedro D, Rondon G, Hong L, Liu S, Champlin RE, Pundole X. Osteoporotic fracture risk assessment using FRAX following hematopoietic stem cell transplantation. European League Against Rheumatism (EULAR) 2017 Annual Meeting, 2017. e-Pub 2017.
- Mohammad A, Yang M, Zhao H, Leo X, Lu H, Suarez-Almazor M. Women with breast cancer initiating therapy with aromatase inhibitors reduces subsequent fracture risk. European League Against Rheumatism (EULAR) 2017 Annual Meeting, 2017. e-Pub 2017.
- Pundole X, Cheema HI, Petitto G, Lopez-Olivo M, Suarez-Almazor ME, Lu H. Prevention and treatment of bone loss and fractures in patients undergoing a hematopoietic stem cell transplant: A systematic review and meta-analysis. American College of Rheumatology Annual Meeting, 2015. e-Pub 2015.
- Pundole XN, Lin H, Barbo A, Champlin RE, Jr M, WA, Lu H. Factors associated with bone fractures following hematopoietic stem cell transplantation. American Society of Clinical Oncology (ASCO) Annual Meeting, 2014. e-Pub 2014.
- Edwards B, Lu H, Saraykar S, Hu M, Gagel R, Murphy Jr WA. Atypical Femur Fractures at UT MD Anderson Cancer Center: A Case Series. 2014 ASCO Annual Meeting, 2014. e-Pub 2014.
- Lu H, Pundole XN. Factors Predicting Long-Term hypogammaglobulinemia in Lymphoma Survivors. AAAAI Annual Meeting, 2014. e-Pub 2014.
- Pundole X, Lu H. Denosumab increases bone mineral density in a woman on dialysis with AML after stem cell transplant. Third Conference on Medical Issues in Cancer Patients and Survivors, 2014. e-Pub 2014.
- Pundole XN, Lin H, Barbo A, Champlin RE, Jr M, WA, Lu H. Both Male and Female Patients Experience High Incidence of Fracture Following Hematopoietic Stem Cell Transplantation. Rolantte and Berdon Lawrence Bone Disease Program Annual Scientific Retreat, 2014. e-Pub 2014.
- Pundole X, Lu H. Vertebral and non-vertebral fractures after hematopoitic stem transplant: A 15-year retrospective study. Annual Research Retreat, Division of Internal Medicine UT MD Anderson Cancer Center, 2013. e-Pub 2013.
- Lu H, Midgen M, Edwards B. Myositis Associated with Hedghog Inhibitors. Second Conference on Medical Issues in Cancer Patients and Survivors, 2013. e-Pub 2013.
- Lu H, Pundole X, Champlin ER, Popat U, Gagel RF. Ibandronate for the prevention of bone loss in patients who received allogeneic stem cell transplantation for hematologic malignancy/disorders. Annual Research Retreat, Division of Internal Medicine UT MD Anderson Cancer Center, 2012. e-Pub 2012.
- Shi Q, Giordano SH, Lu H, Cleeland CH. Aromatase inhibitor-related pain and symptoms impacting impacting work productivity in breast cancer patients. The 11th international aromatase symposium, 2012. e-Pub 2012.
- Shi Q, Giordano SH, Lu H, Cleeland CS. Development of anastrozole-assosiated joint pain and other symptoms in patients with breast cancer. 2012 ASCO Annual Meeting, 2012. e-Pub 2012.
- Lu H, Pundole XN, Vu K. Baseline Characteristic Predictive of Malignancy among patients presenting with lymphadenopathy. Annual Research Retreat, Division of Internal Medicine UT MD Anderson Cancer Center, 2012. e-Pub 2012.
- Lu H, Champlin ER, Popat U, Pundole X, Gagel RF. Ibandronate Reduces Bone Loss Post Allogeneic Stem Cell Transplantation for Hematological Malignancies and Disorders. 10th International Conference on Bone and Mineral Research & 12th International Osteoporosis Symposium, 2012. e-Pub 2012.
- Lu H, Pundole X, Champlin ER, Popat U, Escalante CP, Gagel RF. Ibandronate prevents bone loss of the spine after allogeneic stem cell transplantation for hematologic malignancy/disorders. Rolantte and Berdon Lawrence Bone Disease Program Annual Scientific Retreat, 2012. e-Pub 2012.
- Lu H, Varma A, Popat U, Champlin RE, and Gagel RF. Risk factor for low bone mass in patients with hematological disorders/malignancies during early allogeneic stem cell transplant period. Rolantte and Berdon Lawrence Bone Disease Program Annual Scientific Retreat, 2011. e-Pub 2011.
- Shi Q, Giordano S, Lu H, Cleeland C. Longitudinal change of pain and other symptoms in breast cancer patients with anastrozole treatment. The 33rd Annual San Antonio Breast Cancer Symposium, TX, 2010. e-Pub 2010.
- Lu H, Murphy W. De Quarvein tendinits associated with the use of aromatase inhibitor. Medical Issues in Cancer Survivors, Houston, TX, 2009. e-Pub 2009.
- Lu H, Cabanillas M, Fang S, DU XL. Elderly patients with non-Hodgkin lymphoma who receive chemotherapy are at higher risk for osteoporosis and fractures. The 5th International Conference in Bone and Mineral Research & The 7th International Osteoporosis Symposium, Urumqi-Xinjiang, China, 2007. e-Pub 2007.
- Lu H. Chemotherapy is associated with increased risk of osteoporosis and fracture in elderly patients. The Bone Disease Program of Texas, 5th Annual Scientific Retreat, Houston, TX, 2007. e-Pub 2007.
- Lu H. Rheumatoid vasculitis. CIS Spring School of Autoimmune Diseases, Santa Fe, New Mexico, 2005. e-Pub 2005.
- Lu H. Activated T cells secrete histamine releasing factor. J. Allergy Clin. Immunol 115(2):S220, 2005. e-Pub 2005.
- Lu H, Huston DP, Liu Y. Schistosoma mansoni soluble egg antigen induces TSLP production by fibroblasts. GSK Fellow Symposium, San diego, CA, 2005. e-Pub 2005.
- Lu H, Yang Y, Huston DP, X-F Y. Activated T cells are novel source for secreted histamine releasing factor. Department of Medicine Research Symposium, Houston, TX, 2005. e-Pub 2005.
- Huston DP, Liu Y, Lu H. TGFB1-induced TSLP production. FOCIS centers of excellence trainee satellite symposium, 4th Annual Meeting of the Federation of clinical Immunology Societies/12th Intl Congress of Immunology, Montreal, Canada, 2004. e-Pub 2004.
Book Chapters
- Savannah Bowman, Rodabe N. Amaria, Lu H. Inflammatory Arthritis Post Immune Checkpoint Inhibitor Therapy. In: Challenging Cases in Immunotherapy Related Organ Toxicities, pp 417–423, 2025.
- Lu H, Savannah Bowman, Linda Bobby, Sang T. Kim, Pavlos Msaouel, Tayar Jean. Polymyalgia Rheumatica-Like Syndrome Post Immune Checkpoint Inhibitor Therapy. In: Challenging Cases in Immunotherapy Related Organ Toxicities. Springer, pp 433–438, 2025.
- Yuanteng Jeff Li, Sang T. Kim, Nizar M. Tannir, Lu H. Sicca Syndrome Induced by Immune Checkpoint Inhibitor Therapy. In: Challenging Cases in Immunotherapy Related Organ Toxicities, pp 425–431, 2025.
- Lu, H, Linda Bobby, NP, Tayar, JH, Bowman, S, Kim, ST, Msaouel, P. Polymyalgia Rheumatica-Like Syndrome Post Immune Checkpoint Inhibitor Therapy, 433-438, 2025.
- Li, YJ, Lu, H, Kim, ST, Tannir, NM. Sicca Syndrome Induced by Immune Checkpoint Inhibitor Therapy, 425-431, 2025.
- Bowman, S, Amaria, RN, Lu, H. Inflammatory Arthritis Post Immune Checkpoint Inhibitor Therapy, 417-423, 2025.
- Lu H, Suarez-Almazor M. Rheumatological emergencies. In: Oncologic Emergencies. Springer, 161-179, 2016.
- Waimann C, Lu H, Suarez-Almazor M. Rheumatic Manifestations of Primary and Metastatic Bone Tumors and Paraneoplastic Bone Disease. In: Rheumatic Disease Clinics of North America. 4. Elsevier Publisher, 527-49, 2011.
- Marengo MF, Suarez-Almazor M, Lu H. Neoplastic and Paraneoplastic Synovitis. In: Rheumatic Disease Clinics of North America. 4. Elsevier Publisher, 551-72, 2011.
- Kim ST, Bowman S, Lu H. Immune Checkpoint Inhibitors Induced Rheumatologic Toxicities and Its Management. In: Managing Immunotherapy Related Organ Toxicities: A Practical Guide. Springer Nature.
Letters to the Editor
- Pundole X, Lopez-Olivo MA, Lu H. Calcium and vit D supplements and fracture in community-dwelling adults. JAMA 319: 2041-2042, 2018.
Patient Reviews
CV information above last modified August 28, 2026